TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Director Kenneth Bate of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), currently valued at $8.2 billion, sold 10,090 shares of common stock on August 15, 2025, for approximately $3.65 million. The sales occurred in multiple transactions with prices ranging from $363.4072 to $368.5557, near the stock’s 52-week high of $377.46. The company’s shares have delivered an impressive 51% return over the past year.
On the same day, Bate exercised stock options to acquire 10,000 shares of Madrigal Pharmaceuticals common stock at a price of $16.46 per share, for a total value of $164,600.
Following these transactions, Bate directly owns 2,627 shares of Madrigal Pharmaceuticals.
In other recent news, Madrigal Pharmaceuticals reported second-quarter earnings with Rezdiffra sales significantly exceeding expectations. The company posted Rezdiffra sales of $212.8 million, marking a 55% increase from the previous quarter and surpassing estimates from Goldman Sachs and FactSet. Additionally, Madrigal Pharmaceuticals has entered an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, an oral GLP-1 receptor agonist, with the transaction expected to close in the fourth quarter of 2025. Madrigal also secured a $500 million credit facility with Blue Owl Capital to advance its MASH pipeline, which includes a $350 million initial term loan and a $150 million delayed draw term loan.
Analyst firms have shown optimism, with Piper Sandler reiterating an Overweight rating and Jefferies raising its price target to $502 due to a new patent extension for Rezdiffra. The patent, which extends protection until 2045, has been a key factor in Jefferies’ increased price target. Piper Sandler expressed confidence in the ongoing launch of Rezdiffra, aligning with current market projections. These developments highlight Madrigal’s strategic initiatives and financial maneuvers in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.